1.      Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and preval-ence. J Invest Dermatol 2013; 133:377.

2.      Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010;76:595–601

3.      Kaur I, Handa S, Kumar B. Natural history of psoriasis: a study from the Indian subcontinent. J Dermatol 1997;24:230-4. 

4.      Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. Br J Dermatol.2006;155(4):729-736.

5.      Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009 Oct;23(suppl 2):1e70.

6.      C. E. Griffiths and J. N. Barker, “Patho-genesis and clinical features of psoriasis,” Lancet, vol 370, no. 9583, pp. 263–271, 2007.

7.      M. P. Sch¨on and W. H. Boehncke, “Psori-asis,” The New England Journal of Medic-ine, vol. 352, no. 18, pp. 1899–1912, 2005.

8.      W. Abramovits, “Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy,” Journal of Drugs in Dermat-ology, vol. 8, supplement 8, pp. s17–s22, 2009.

9.      P. C. M. Van De Kerkhof, “The topical treatment of psoriasis,” Clinical and Experimental Dermatology, vol. 30, no. 2, pp. 205– 208, 2005.

10.  E. A. Tanghetti, “The role of topical vitamin D modulator in psoriasis therapy,” Journal of Drugs in Dermatology, vol. 8 supplement 8, pp. s4–s8, 2009.

11.  Trémezaygues L, Reichrath J. Vitamin D analogues in treatment of psoriasis. Where are we standing and where will we be going. Dermatoendocrinology 2011;3:180-6.

12.  B. Lehmann, “Role of the vitamin D pathway in healthy and diseased skin—facts, contradictions and hypotheses,” Experimental Dermatology, vol. 18, no. 2, pp. 97–108, 2009

13.  Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3μg/g ointment in the manage-ment of mild to moderate plaque type psoriasisi: results from two placebo-controlled, multicenter, randomized, double-blind, clinical studies. J Drugs Dermatol. 2007;6(4):428–435.

14.  Ortonne JP, Humbert P, Nicolas JF, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3μg/g ointment and calcipotriol 50μg/g ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol. 2003;148(2):326–333.

15.  Lebwohl M, Ortonne JP, Andres P, Briantais P. Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis 2009; 83:205.